BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 15863798)

  • 1. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
    Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
    Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
    Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
    Henderson DC; Fan X; Copeland PM; Borba CP; Daley TB; Nguyen DD; Zhang H; Hayden D; Freudenreich O; Cather C; Evins AE; Goff DC
    Acta Psychiatr Scand; 2007 Feb; 115(2):101-5. PubMed ID: 17244173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
    Ball MP; Warren KR; Feldman S; McMahon RP; Kelly DL; Buchanan RW
    Clin Schizophr Relat Psychoses; 2011 Apr; 5(1):17-25. PubMed ID: 21459735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
    Berkowitz RI; Wadden TA; Tershakovec AM; Cronquist JL
    JAMA; 2003 Apr; 289(14):1805-12. PubMed ID: 12684359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
    McElroy SL; Frye MA; Altshuler LL; Suppes T; Hellemann G; Black D; Mintz J; Kupka R; Nolen W; Leverich GS; Denicoff KD; Post RM; Keck PE
    Bipolar Disord; 2007 Jun; 9(4):426-34. PubMed ID: 17547588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study.
    Wilfley DE; Crow SJ; Hudson JI; Mitchell JE; Berkowitz RI; Blakesley V; Walsh BT;
    Am J Psychiatry; 2008 Jan; 165(1):51-8. PubMed ID: 18056225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia.
    Biedermann F; Fleischhacker WW; Kemmler G; Ebenbichler CF; Lechleitner M; Hofer A
    Int Clin Psychopharmacol; 2014 May; 29(3):181-4. PubMed ID: 24300751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term weight loss with sibutramine: a randomized controlled trial.
    Wirth A; Krause J
    JAMA; 2001 Sep; 286(11):1331-9. PubMed ID: 11560538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
    Graham KA; Gu H; Lieberman JA; Harp JB; Perkins DO
    Am J Psychiatry; 2005 Sep; 162(9):1744-6. PubMed ID: 16135638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.